Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications

Fineline Cube Aug 4, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China

Fineline Cube Aug 4, 2026
Company Drug

Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership

Fineline Cube Aug 4, 2026
Company Deals

Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China

Fineline Cube Nov 7, 2022

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co.,...

Company

Novo Nordisk to Invest RMB 400M in Shanghai at CIIE

Fineline Cube Nov 7, 2022

Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...

Company Drug

Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection

Fineline Cube Nov 7, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...

Company Drug

Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA

Fineline Cube Nov 7, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...

Company Drug

Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study

Fineline Cube Nov 4, 2022

China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...

Company Deals

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Policy / Regulatory

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Company Drug

Sinovac’s Varicella Vaccine Receives WHO Pre-Qualification

Fineline Cube Nov 4, 2022

China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...

Company Drug

Reforgene Medicine RM-001 Thalassemia Gene Editing

Fineline Cube Nov 4, 2022

China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...

Company Drug

Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine

Fineline Cube Nov 4, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...

Company Drug

Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19

Fineline Cube Nov 4, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized,...

Company

Bloomage Biotech CEO Investigated Over Discounted Share Sales

Fineline Cube Nov 4, 2022

The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao...

Policy / Regulatory

NMPA Proposes ‘Drug Online Sales Blacklist’ for Public Feedback

Fineline Cube Nov 4, 2022

The National Medical Products Administration (NMPA) has released a draft proposal for a “Drug Online...

Company Drug

Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH

Fineline Cube Nov 4, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...

Company Drug

Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma

Fineline Cube Nov 4, 2022

China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...

Company Drug

Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials

Fineline Cube Nov 4, 2022

China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy,...

Company Deals

Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products

Fineline Cube Nov 4, 2022

Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology...

Company Deals

Yaguo Technology Secures Series A+ Funding for Airway Management Devices

Fineline Cube Nov 4, 2022

Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...

Company Deals

Novatim Immune Therapeutics Raises RMB 500M in First Financing Round

Fineline Cube Nov 4, 2022

China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...

Company Deals

Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round

Fineline Cube Nov 4, 2022

Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...

Posts pagination

1 … 642 643 644 … 702

Recent updates

  • CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China
  • NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications
  • Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership
  • Jinling Pharmaceutical’s Ferric Carboxymaltose Injection Receives NMPA Acceptance for Market Authorization
  • Mabwell (Shanghai) Bioscience Secures NMPA Approval for 9MW5211 Clinical Trials in Primary Biliary Cholangitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China

Policy / Regulatory

NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications

Company Drug

Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership

Company Drug

Jinling Pharmaceutical’s Ferric Carboxymaltose Injection Receives NMPA Acceptance for Market Authorization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.